search
Back to results

A Study on The Safety of Administering Rituximab at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)

Primary Purpose

Rheumatoid Arthritis

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
rituximab
methotrexate
methylprednisolone
acetaminophen
antihistamine
Sponsored by
Hoffmann-La Roche
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Rheumatoid Arthritis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Key Inclusion Criteria:

  • Adult patients, ≥ 18 years of age
  • Rheumatoid arthritis of ≥ 6 months duration, diagnosed according to the revised 1987 American College of Rheumatology criteria
  • Inadequate response to at least one approved anti-TNF agent (adalimumab, etanercept, infliximab, golimumab, or certolizumab)
  • Patients who have received 1 to 2 prior courses of rituximab (RTX) may be enrolled, provided their most recent course of RTX occurred over 6 months but no more than 9 months prior to baseline. The RTX dosage must have been two 1000 mg infusions per course administered at the standard approved rate
  • Methotrexate treatment between 10 and 25 mg/week (oral or parenteral) for at least 8 weeks immediately prior to baseline

Key Exclusion Criteria:

  • Major surgery (including joint surgery) within 8 weeks prior to screening or planned surgery within 6 months following baseline
  • Rheumatic autoimmune disease other than rheumatoid arthritis
  • Functional class IV as defined by American College of Rheumatology (ACR) criteria
  • Prior history of or current inflammatory joint disease other than rheumatoid arthritis
  • History of severe allergic or anaphylactic reactions to human, humanized or murine monoclonal antibodies
  • Previous serious infusion reaction to any prior biologic therapy
  • Known active current or history of recurrent infection
  • Evidence of chronic hepatitis B or C infection
  • Pregnant or lactating women
  • Body weight of > 150 kg

Sites / Locations

  • Uni Of Alabama,Birmingham; Medicine - Rheumatology
  • Clnical & Translational Reseach Center for Alabama, PC
  • ArthroCare, Arthritis Care; and Research P.C.
  • Valley Arthritis Care
  • Catalina Pointe Rheumatology
  • Medvin Clinical Research
  • Triwest Research Associates
  • Medvin Clinical Research
  • Brigid Freyne-Private Practice; Internal Medicine, Rheum
  • Desert Medical Advances; Rheumatology
  • San Diego Arthritis Med Clnc
  • Pacific Arthritis Ctr Med Grp
  • Inland Rheumatology; Clinical Trials, Inc.
  • Medvin Clinical Research
  • Arthritis Assoc & Osteoporosis; Ctr of Colorado Springs
  • Denver Arthritis Clinic
  • Rheum & Internal Med Assoc-Bri
  • Arthritis & Osteoporosis Center Pc
  • Rheumatolgy Consultants of Deleware
  • Javed Rheumatology Associates, Inc.
  • Arthritis & Rheumatism; Disease Specialities
  • Florida Arthritis Center, PI
  • Omega ResearchConsultants LLC
  • Millenium Research
  • Arthritis Center Palm Harbor
  • Arthritis Rsrch of Florida, Inc.
  • Center For Arthritis; Research Dept
  • University of South Florida
  • Florida Medical Clinic; Clinical Research
  • Parris & Associates
  • St. Luke's Intermountain Research Center
  • Institute of Arthritis Research
  • Quad City Rheumatology, Sc
  • Physician'S Clinic of Iowa
  • Bluegrass Comm Research, Inc.
  • Klein & Associates, M.D. P.A.
  • Klein & Associates, M.D., P.A.
  • St. Luke's Hospital Association of Duluth
  • Arthritis and Osteoporosis; Treatment and Research Center
  • Jackson Arthritis Clinic
  • North Mississippi Med Clinics, Inc.
  • David S Rosenberg
  • Arthritis Center of Reno
  • Rheumatology Research Group
  • Rheumatology Associates Of New Jersey
  • The Center for Rheumatology
  • Arthritis & Osteoporosis Center
  • NYU Center for Musculoskeletal Care
  • Buffalo Rheumatology Associates
  • Office of Premier Chatpar Md
  • Aair Research Center
  • Rheumatology Associates of Long Island
  • Arthritis Health Associates; Clinical Research
  • Arth&OsteoConsof theCarolinas-Charlotte
  • Box Arthritis & Rheumatology
  • Carolina Bone & Joint P.A.
  • Physicians East Pa
  • Shanahan Rheumatology & Immunology, PLLC
  • Crystal Arthritis Center, Inc.
  • CarePoint East
  • Stat Research, Inc
  • Paramount Medical Research
  • LION Research
  • Arthritis and Rheumatology; Center of Oklahoma PLLC
  • East Penn Rheumatology Associates, Pc
  • Altoona Center For Clinical Research
  • Pivotal Clinical Research, Llc
  • Arthritis Group
  • Rheumatic Disease Associates; Clinical Research Unit
  • Clinical Research Center of Reading
  • Pennsylvania Regional Center for Arthritis and Osteoporosis Research
  • Low Country Rheumatology, PA
  • Rheumatology Associates
  • West Tennessee Research Institute
  • Ramesh Gupta - PP
  • Amarillo Center For Clinical Research
  • Lovelace Scientific Resources Inc.
  • Adriana Pop-Moody MD Clinic PA
  • Arthritis Centers of Texas
  • Southwest Rheumatology
  • Arthritis Clinic of Northern Virginia
  • Apex Clinical Research
  • Seattle Arthritis Clinic
  • Arthritis Northwest, Spokane
  • Cedar Medical Center
  • Rheumatic Disease Center

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Rituximab

Arm Description

Rituximab intravenous (IV) infusions were administered over a 4.25-hour period on Day 1, and over a 2-hour period on Day 15 (first course) and on Days 168 and 182 (second course). All participants continued to receive methotrexate as prescribed by their treating physician. Premedication included methylprednisolone, an antihistamine and acetaminophen.

Outcomes

Primary Outcome Measures

Percentage of Participants Experiencing Any Infusion-related Reaction (IRR) Associated With the Second Rituximab Infusion
The primary criterion for assessing safety of the faster infusion was the incidence of infusion related reaction (IRRs). IRRs were adverse events (AEs) that occurred within 24 hours of beginning infusion that were among a pre-specified list of preferred terms from the Medical Dictionary for Regulatory Activities (MedDRA). "Incidence" is defined as the percentage of participants experiencing an IRR.

Secondary Outcome Measures

Percentage of Participants Experiencing Any Serious IRR (SIRR) Associated With the Second Rituximab Infusion
A serious infusion-related reaction (SIRR) is an IRR that meets the definition of a serious adverse event. A serious adverse event (SAE) is any experience that suggests a significant hazard, contraindication, side effect or precaution.
Percentage of Participants Experiencing Any IRR or SIRR Associated With the Third Rituximab Infusion
IRRs are AEs that occurred within 24 hours of beginning infusion that were included on a pre-specified list of MedDRA preferred terms, and an SIRR is an IRR that suggests a significant hazard, contraindication, side effect or precaution.
Percentage of Participants Experiencing Any Common Toxicity Criteria (CTC) Grade 3 or 4 Adverse Events (AEs) Associated With the Second Rituximab Infusion
The intensity of AEs were graded on a 5-point scale (Grade 1 to 5) according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v. 4.0), where Grade 1 indicates "Mild" severity and Grade 5 indicates "Death". The CTCAE defines Grades 3 and 4 as follows: - Grade 3 means "Severe", indicating considerable interference with the patient's daily activities; medical intervention/therapy required; and hospitalization possible. - Grade 4 means "Life-threatening, Disabling", based on extreme limitation in activity; significant medical intervention/therapy required, and hospitalization probable.
Percentage of Participants Experiencing the Stopping, Slowing or Interrupting of the Second Rituximab Infusion
Participants who experienced a moderate or serious IRR had their infusion interrupted immediately and received aggressive symptomatic treatment. The CTCAE includes the following severity descriptions: - "Moderate" means mild to moderate interference with the patient's daily activities, no or minimal medical intervention/therapy required; - "Severe" means considerable interference with the patient's daily activities, medical intervention/therapy required, hospitalization possible. If the IRR was moderate, the infusion was not to be restarted before all the symptoms disappeared, and then at half the rate. If the participant tolerated the reduced rate for 30 minutes, the infusion rate was increased to the next rate on the protocol-specified infusion schedule. If the symptoms did not resolve with treatment, the participant was withdrawn from the treatment period of the study. Participants who experienced a severe IRR to rituximab treatment were discontinued from the study.
Percentage of Participants Experiencing Any Common Toxicity Criteria (CTC) Grade 3 or 4 Adverse Events (AEs) Associated With the Third Rituximab Infusion
The intensity of AEs experienced within 24 hours of beginning infusion were graded on NCI's CTCAE (v. 4.0) intensity scale from Grade 1 ("Mild") to Grade 5 ("Death"). Grade 3 AEs are "Severe" and Grade 4 AEs are "Life-threatening, Disabling".
Percentage of Participants Experiencing the Stopping, Slowing or Interrupting of the Third Rituximab Infusion
Participants who experienced a moderate or serious IRR had their infusion interrupted immediately and received aggressive symptomatic treatment. The CTCAE includes the following severity descriptions: - "Moderate" means mild to moderate interference with the patient's daily activities, no or minimal medical intervention/therapy required; - "Severe" means considerable interference with the patient's daily activities, medical intervention/therapy required, hospitalization possible. If the IRR was moderate, the infusion was not to be restarted before all the symptoms disappeared, and then at half the rate. If the participant tolerated the reduced rate for 30 minutes, the infusion rate was increased to the next rate on the protocol-specified infusion schedule. If the symptoms did not resolve with treatment, the participant was withdrawn from the treatment period of the study. Participants who experienced a severe IRR to rituximab treatment were discontinued from the study.

Full Information

First Posted
June 24, 2011
Last Updated
July 5, 2017
Sponsor
Hoffmann-La Roche
search

1. Study Identification

Unique Protocol Identification Number
NCT01382940
Brief Title
A Study on The Safety of Administering Rituximab at A More Rapid Rate in Patients With Rheumatoid Arthritis
Acronym
RATE-RA
Official Title
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Study Type
Interventional

2. Study Status

Record Verification Date
July 2017
Overall Recruitment Status
Completed
Study Start Date
July 26, 2011 (Actual)
Primary Completion Date
January 6, 2013 (Actual)
Study Completion Date
January 6, 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hoffmann-La Roche

4. Oversight

5. Study Description

Brief Summary
This study was designed to evaluate the safety of administering rituximab at a more rapid infusion rate in patients with moderate to severe rheumatoid arthritis who have had an inadequate response to biopharmaceuticals that treat diseases by interfering with tumor necrosis factor (anti-TNF therapies), and were receiving methotrexate therapy for more than eight weeks.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Rheumatoid Arthritis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
351 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Rituximab
Arm Type
Experimental
Arm Description
Rituximab intravenous (IV) infusions were administered over a 4.25-hour period on Day 1, and over a 2-hour period on Day 15 (first course) and on Days 168 and 182 (second course). All participants continued to receive methotrexate as prescribed by their treating physician. Premedication included methylprednisolone, an antihistamine and acetaminophen.
Intervention Type
Drug
Intervention Name(s)
rituximab
Other Intervention Name(s)
Rituxan®, MabThera®
Intervention Description
1000 mg in 250 mL intravenous infusion
Intervention Type
Drug
Intervention Name(s)
methotrexate
Intervention Description
10 to 25 mg/week (oral or parenteral)
Intervention Type
Drug
Intervention Name(s)
methylprednisolone
Intervention Description
100 mg methylprednisolone administered by slow intravenous infusion at least 30 minutes prior to the start of each study drug infusion
Intervention Type
Drug
Intervention Name(s)
acetaminophen
Intervention Description
1 gram acetaminophen administered orally 30 to 60 minutes prior to the start of each study drug infusion
Intervention Type
Drug
Intervention Name(s)
antihistamine
Intervention Description
50 mg diphenhydramine hydrochloride or equivalent dose of alternate antihistamine administered orally 30 to 60 minutes prior to the start of each study drug infusion
Primary Outcome Measure Information:
Title
Percentage of Participants Experiencing Any Infusion-related Reaction (IRR) Associated With the Second Rituximab Infusion
Description
The primary criterion for assessing safety of the faster infusion was the incidence of infusion related reaction (IRRs). IRRs were adverse events (AEs) that occurred within 24 hours of beginning infusion that were among a pre-specified list of preferred terms from the Medical Dictionary for Regulatory Activities (MedDRA). "Incidence" is defined as the percentage of participants experiencing an IRR.
Time Frame
Within 24 hours of beginning infusion on Day 15
Secondary Outcome Measure Information:
Title
Percentage of Participants Experiencing Any Serious IRR (SIRR) Associated With the Second Rituximab Infusion
Description
A serious infusion-related reaction (SIRR) is an IRR that meets the definition of a serious adverse event. A serious adverse event (SAE) is any experience that suggests a significant hazard, contraindication, side effect or precaution.
Time Frame
Within 24 hours of beginning infusion on Day 15
Title
Percentage of Participants Experiencing Any IRR or SIRR Associated With the Third Rituximab Infusion
Description
IRRs are AEs that occurred within 24 hours of beginning infusion that were included on a pre-specified list of MedDRA preferred terms, and an SIRR is an IRR that suggests a significant hazard, contraindication, side effect or precaution.
Time Frame
Within 24 hours of beginning infusion on Day 168
Title
Percentage of Participants Experiencing Any Common Toxicity Criteria (CTC) Grade 3 or 4 Adverse Events (AEs) Associated With the Second Rituximab Infusion
Description
The intensity of AEs were graded on a 5-point scale (Grade 1 to 5) according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v. 4.0), where Grade 1 indicates "Mild" severity and Grade 5 indicates "Death". The CTCAE defines Grades 3 and 4 as follows: - Grade 3 means "Severe", indicating considerable interference with the patient's daily activities; medical intervention/therapy required; and hospitalization possible. - Grade 4 means "Life-threatening, Disabling", based on extreme limitation in activity; significant medical intervention/therapy required, and hospitalization probable.
Time Frame
Within 24 hours of beginning infusion on Day 15
Title
Percentage of Participants Experiencing the Stopping, Slowing or Interrupting of the Second Rituximab Infusion
Description
Participants who experienced a moderate or serious IRR had their infusion interrupted immediately and received aggressive symptomatic treatment. The CTCAE includes the following severity descriptions: - "Moderate" means mild to moderate interference with the patient's daily activities, no or minimal medical intervention/therapy required; - "Severe" means considerable interference with the patient's daily activities, medical intervention/therapy required, hospitalization possible. If the IRR was moderate, the infusion was not to be restarted before all the symptoms disappeared, and then at half the rate. If the participant tolerated the reduced rate for 30 minutes, the infusion rate was increased to the next rate on the protocol-specified infusion schedule. If the symptoms did not resolve with treatment, the participant was withdrawn from the treatment period of the study. Participants who experienced a severe IRR to rituximab treatment were discontinued from the study.
Time Frame
During the infusion (a 2-hour period) on Day 15
Title
Percentage of Participants Experiencing Any Common Toxicity Criteria (CTC) Grade 3 or 4 Adverse Events (AEs) Associated With the Third Rituximab Infusion
Description
The intensity of AEs experienced within 24 hours of beginning infusion were graded on NCI's CTCAE (v. 4.0) intensity scale from Grade 1 ("Mild") to Grade 5 ("Death"). Grade 3 AEs are "Severe" and Grade 4 AEs are "Life-threatening, Disabling".
Time Frame
Within 24 hours of beginning infusion on Day 168
Title
Percentage of Participants Experiencing the Stopping, Slowing or Interrupting of the Third Rituximab Infusion
Description
Participants who experienced a moderate or serious IRR had their infusion interrupted immediately and received aggressive symptomatic treatment. The CTCAE includes the following severity descriptions: - "Moderate" means mild to moderate interference with the patient's daily activities, no or minimal medical intervention/therapy required; - "Severe" means considerable interference with the patient's daily activities, medical intervention/therapy required, hospitalization possible. If the IRR was moderate, the infusion was not to be restarted before all the symptoms disappeared, and then at half the rate. If the participant tolerated the reduced rate for 30 minutes, the infusion rate was increased to the next rate on the protocol-specified infusion schedule. If the symptoms did not resolve with treatment, the participant was withdrawn from the treatment period of the study. Participants who experienced a severe IRR to rituximab treatment were discontinued from the study.
Time Frame
During the infusion (a 2-hour period) on Day 168

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Key Inclusion Criteria: Adult patients, ≥ 18 years of age Rheumatoid arthritis of ≥ 6 months duration, diagnosed according to the revised 1987 American College of Rheumatology criteria Inadequate response to at least one approved anti-TNF agent (adalimumab, etanercept, infliximab, golimumab, or certolizumab) Patients who have received 1 to 2 prior courses of rituximab (RTX) may be enrolled, provided their most recent course of RTX occurred over 6 months but no more than 9 months prior to baseline. The RTX dosage must have been two 1000 mg infusions per course administered at the standard approved rate Methotrexate treatment between 10 and 25 mg/week (oral or parenteral) for at least 8 weeks immediately prior to baseline Key Exclusion Criteria: Major surgery (including joint surgery) within 8 weeks prior to screening or planned surgery within 6 months following baseline Rheumatic autoimmune disease other than rheumatoid arthritis Functional class IV as defined by American College of Rheumatology (ACR) criteria Prior history of or current inflammatory joint disease other than rheumatoid arthritis History of severe allergic or anaphylactic reactions to human, humanized or murine monoclonal antibodies Previous serious infusion reaction to any prior biologic therapy Known active current or history of recurrent infection Evidence of chronic hepatitis B or C infection Pregnant or lactating women Body weight of > 150 kg
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clinical Trials
Organizational Affiliation
Hoffmann-La Roche
Official's Role
Study Director
Facility Information:
Facility Name
Uni Of Alabama,Birmingham; Medicine - Rheumatology
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35294
Country
United States
Facility Name
Clnical & Translational Reseach Center for Alabama, PC
City
Tuscaloosa
State/Province
Alabama
ZIP/Postal Code
35406
Country
United States
Facility Name
ArthroCare, Arthritis Care; and Research P.C.
City
Gilbert
State/Province
Arizona
ZIP/Postal Code
85234
Country
United States
Facility Name
Valley Arthritis Care
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85027
Country
United States
Facility Name
Catalina Pointe Rheumatology
City
Tucson
State/Province
Arizona
ZIP/Postal Code
85704
Country
United States
Facility Name
Medvin Clinical Research
City
Covina
State/Province
California
ZIP/Postal Code
91723
Country
United States
Facility Name
Triwest Research Associates
City
La Mesa
State/Province
California
ZIP/Postal Code
91942
Country
United States
Facility Name
Medvin Clinical Research
City
Los Angeles
State/Province
California
ZIP/Postal Code
90048
Country
United States
Facility Name
Brigid Freyne-Private Practice; Internal Medicine, Rheum
City
Murrieta
State/Province
California
ZIP/Postal Code
92563
Country
United States
Facility Name
Desert Medical Advances; Rheumatology
City
Palm Desert
State/Province
California
ZIP/Postal Code
92260
Country
United States
Facility Name
San Diego Arthritis Med Clnc
City
San Diego
State/Province
California
ZIP/Postal Code
92108
Country
United States
Facility Name
Pacific Arthritis Ctr Med Grp
City
Santa Maria
State/Province
California
ZIP/Postal Code
93454
Country
United States
Facility Name
Inland Rheumatology; Clinical Trials, Inc.
City
Upland
State/Province
California
ZIP/Postal Code
91786
Country
United States
Facility Name
Medvin Clinical Research
City
Whittier
State/Province
California
ZIP/Postal Code
90606
Country
United States
Facility Name
Arthritis Assoc & Osteoporosis; Ctr of Colorado Springs
City
Colorado Springs
State/Province
Colorado
ZIP/Postal Code
80920
Country
United States
Facility Name
Denver Arthritis Clinic
City
Denver
State/Province
Colorado
ZIP/Postal Code
80230-7127
Country
United States
Facility Name
Rheum & Internal Med Assoc-Bri
City
Bridgeport
State/Province
Connecticut
ZIP/Postal Code
06606
Country
United States
Facility Name
Arthritis & Osteoporosis Center Pc
City
Hamden
State/Province
Connecticut
ZIP/Postal Code
06518
Country
United States
Facility Name
Rheumatolgy Consultants of Deleware
City
Lewes
State/Province
Delaware
ZIP/Postal Code
19958
Country
United States
Facility Name
Javed Rheumatology Associates, Inc.
City
Newark
State/Province
Delaware
ZIP/Postal Code
19713
Country
United States
Facility Name
Arthritis & Rheumatism; Disease Specialities
City
Aventura
State/Province
Florida
ZIP/Postal Code
33180
Country
United States
Facility Name
Florida Arthritis Center, PI
City
Lake Mary
State/Province
Florida
ZIP/Postal Code
32746
Country
United States
Facility Name
Omega ResearchConsultants LLC
City
Orlando
State/Province
Florida
ZIP/Postal Code
32804
Country
United States
Facility Name
Millenium Research
City
Ormond Beach
State/Province
Florida
ZIP/Postal Code
32174
Country
United States
Facility Name
Arthritis Center Palm Harbor
City
Palm Harbor
State/Province
Florida
ZIP/Postal Code
34684
Country
United States
Facility Name
Arthritis Rsrch of Florida, Inc.
City
Palm Harbor
State/Province
Florida
ZIP/Postal Code
34684
Country
United States
Facility Name
Center For Arthritis; Research Dept
City
South Miami
State/Province
Florida
ZIP/Postal Code
33143
Country
United States
Facility Name
University of South Florida
City
Tampa
State/Province
Florida
ZIP/Postal Code
33612
Country
United States
Facility Name
Florida Medical Clinic; Clinical Research
City
Zephyrhills
State/Province
Florida
ZIP/Postal Code
33613
Country
United States
Facility Name
Parris & Associates
City
Lawrenceville
State/Province
Georgia
ZIP/Postal Code
30046
Country
United States
Facility Name
St. Luke's Intermountain Research Center
City
Boise
State/Province
Idaho
ZIP/Postal Code
83702
Country
United States
Facility Name
Institute of Arthritis Research
City
Idaho Falls
State/Province
Idaho
ZIP/Postal Code
83404
Country
United States
Facility Name
Quad City Rheumatology, Sc
City
Moline
State/Province
Illinois
ZIP/Postal Code
61265
Country
United States
Facility Name
Physician'S Clinic of Iowa
City
Cedar Rapids
State/Province
Iowa
ZIP/Postal Code
52401
Country
United States
Facility Name
Bluegrass Comm Research, Inc.
City
Lexington
State/Province
Kentucky
ZIP/Postal Code
40515
Country
United States
Facility Name
Klein & Associates, M.D. P.A.
City
Cumberland
State/Province
Maryland
ZIP/Postal Code
21502
Country
United States
Facility Name
Klein & Associates, M.D., P.A.
City
Hagerstown
State/Province
Maryland
ZIP/Postal Code
21740
Country
United States
Facility Name
St. Luke's Hospital Association of Duluth
City
Duluth
State/Province
Minnesota
ZIP/Postal Code
55805
Country
United States
Facility Name
Arthritis and Osteoporosis; Treatment and Research Center
City
Flowood
State/Province
Mississippi
ZIP/Postal Code
39232
Country
United States
Facility Name
Jackson Arthritis Clinic
City
Flowood
State/Province
Mississippi
ZIP/Postal Code
39232
Country
United States
Facility Name
North Mississippi Med Clinics, Inc.
City
Tupelo
State/Province
Mississippi
ZIP/Postal Code
38801
Country
United States
Facility Name
David S Rosenberg
City
Florissant
State/Province
Missouri
ZIP/Postal Code
63031
Country
United States
Facility Name
Arthritis Center of Reno
City
Reno
State/Province
Nevada
ZIP/Postal Code
89502
Country
United States
Facility Name
Rheumatology Research Group
City
Lebanon
State/Province
New Hampshire
ZIP/Postal Code
03756
Country
United States
Facility Name
Rheumatology Associates Of New Jersey
City
Teaneck
State/Province
New Jersey
ZIP/Postal Code
07666
Country
United States
Facility Name
The Center for Rheumatology
City
Albany
State/Province
New York
ZIP/Postal Code
12203
Country
United States
Facility Name
Arthritis & Osteoporosis Center
City
Brooklyn
State/Province
New York
ZIP/Postal Code
11201
Country
United States
Facility Name
NYU Center for Musculoskeletal Care
City
New York
State/Province
New York
ZIP/Postal Code
10003
Country
United States
Facility Name
Buffalo Rheumatology Associates
City
Orchard Park
State/Province
New York
ZIP/Postal Code
14127
Country
United States
Facility Name
Office of Premier Chatpar Md
City
Plainview
State/Province
New York
ZIP/Postal Code
11803
Country
United States
Facility Name
Aair Research Center
City
Rochester
State/Province
New York
ZIP/Postal Code
14618
Country
United States
Facility Name
Rheumatology Associates of Long Island
City
Smithtown
State/Province
New York
ZIP/Postal Code
11787
Country
United States
Facility Name
Arthritis Health Associates; Clinical Research
City
Syracuse
State/Province
New York
ZIP/Postal Code
13210
Country
United States
Facility Name
Arth&OsteoConsof theCarolinas-Charlotte
City
Charlotte
State/Province
North Carolina
ZIP/Postal Code
28207
Country
United States
Facility Name
Box Arthritis & Rheumatology
City
Charlotte
State/Province
North Carolina
ZIP/Postal Code
28210
Country
United States
Facility Name
Carolina Bone & Joint P.A.
City
Charlotte
State/Province
North Carolina
ZIP/Postal Code
28210
Country
United States
Facility Name
Physicians East Pa
City
Greenville
State/Province
North Carolina
ZIP/Postal Code
27834
Country
United States
Facility Name
Shanahan Rheumatology & Immunology, PLLC
City
Raleigh
State/Province
North Carolina
ZIP/Postal Code
27617
Country
United States
Facility Name
Crystal Arthritis Center, Inc.
City
Akron
State/Province
Ohio
ZIP/Postal Code
44333
Country
United States
Facility Name
CarePoint East
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43203
Country
United States
Facility Name
Stat Research, Inc
City
Dayton
State/Province
Ohio
ZIP/Postal Code
45402
Country
United States
Facility Name
Paramount Medical Research
City
Middleburg Heights
State/Province
Ohio
ZIP/Postal Code
44130
Country
United States
Facility Name
LION Research
City
Norman
State/Province
Oklahoma
ZIP/Postal Code
73069
Country
United States
Facility Name
Arthritis and Rheumatology; Center of Oklahoma PLLC
City
Oklahoma City
State/Province
Oklahoma
ZIP/Postal Code
73103
Country
United States
Facility Name
East Penn Rheumatology Associates, Pc
City
Bethlehem
State/Province
Pennsylvania
ZIP/Postal Code
18015
Country
United States
Facility Name
Altoona Center For Clinical Research
City
Duncansville
State/Province
Pennsylvania
ZIP/Postal Code
16635
Country
United States
Facility Name
Pivotal Clinical Research, Llc
City
Perkasie
State/Province
Pennsylvania
ZIP/Postal Code
18944
Country
United States
Facility Name
Arthritis Group
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19152
Country
United States
Facility Name
Rheumatic Disease Associates; Clinical Research Unit
City
Willow Grove
State/Province
Pennsylvania
ZIP/Postal Code
19090
Country
United States
Facility Name
Clinical Research Center of Reading
City
Wyomissing
State/Province
Pennsylvania
ZIP/Postal Code
19610
Country
United States
Facility Name
Pennsylvania Regional Center for Arthritis and Osteoporosis Research
City
Wyomissing
State/Province
Pennsylvania
ZIP/Postal Code
19610
Country
United States
Facility Name
Low Country Rheumatology, PA
City
Charleston
State/Province
South Carolina
ZIP/Postal Code
29406
Country
United States
Facility Name
Rheumatology Associates
City
Charleston
State/Province
South Carolina
ZIP/Postal Code
29407
Country
United States
Facility Name
West Tennessee Research Institute
City
Jackson
State/Province
Tennessee
ZIP/Postal Code
38305
Country
United States
Facility Name
Ramesh Gupta - PP
City
Memphis
State/Province
Tennessee
ZIP/Postal Code
38119
Country
United States
Facility Name
Amarillo Center For Clinical Research
City
Amarillo
State/Province
Texas
ZIP/Postal Code
79124
Country
United States
Facility Name
Lovelace Scientific Resources Inc.
City
Austin
State/Province
Texas
ZIP/Postal Code
78758
Country
United States
Facility Name
Adriana Pop-Moody MD Clinic PA
City
Corpus Christi
State/Province
Texas
ZIP/Postal Code
78404
Country
United States
Facility Name
Arthritis Centers of Texas
City
Dallas
State/Province
Texas
ZIP/Postal Code
75246
Country
United States
Facility Name
Southwest Rheumatology
City
Mesquite
State/Province
Texas
ZIP/Postal Code
75150
Country
United States
Facility Name
Arthritis Clinic of Northern Virginia
City
Arlington
State/Province
Virginia
ZIP/Postal Code
22205
Country
United States
Facility Name
Apex Clinical Research
City
Kennewick
State/Province
Washington
ZIP/Postal Code
99336
Country
United States
Facility Name
Seattle Arthritis Clinic
City
Seattle
State/Province
Washington
ZIP/Postal Code
98133
Country
United States
Facility Name
Arthritis Northwest, Spokane
City
Spokane
State/Province
Washington
ZIP/Postal Code
99204
Country
United States
Facility Name
Cedar Medical Center
City
Tacoma
State/Province
Washington
ZIP/Postal Code
98405
Country
United States
Facility Name
Rheumatic Disease Center
City
Glendale
State/Province
Wisconsin
ZIP/Postal Code
53217
Country
United States

12. IPD Sharing Statement

Learn more about this trial

A Study on The Safety of Administering Rituximab at A More Rapid Rate in Patients With Rheumatoid Arthritis

We'll reach out to this number within 24 hrs